Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 4/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PDE6D | O43924 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883817 | 0.91 | NPY1R (0.53) | NPY1RMCHR1LTA4HTP53MAPT | |
| SCHEMBL5883736 | 0.87 | NPY1R (0.50) | NPY1RMCHR1LTA4HTP53MAPT | |
| SCHEMBL5883568 | 0.85 | NPY1R (0.48) | NPY1RMCHR1SCN9ALTA4HTP53 | |
| SCHEMBL5883733 | 0.84 | NPY1R (0.58) | NPY1RMCHR1LTA4HTP53MAPT | |
| SCHEMBL5884179 | 0.82 | NPY1R (0.57) | NPY1RMCHR1TP53MAPTPDE6D | |
| SCHEMBL5883766 | 0.82 | HDAC1 (0.52) | NPY1RMCHR1GRM2DRD2DRD3 | |
| SCHEMBL5884145 | 0.80 | NPY1R (0.55) | NPY1RMCHR1SCN9ALTA4HDRD2 | |
| SCHEMBL29056704 | 0.79 | TP53 (0.58) | NPY1RMCHR1TP53MAPTPDE6D | |
| SCHEMBL5883779 | 0.78 | PDE6D (0.39) | SCN9AMAPTPDE6DCHEK2 | |
| SCHEMBL5883938 | 0.73 | PTGER4 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022714-B2 | Aryl substituted benzimidazoles and their use as sodium channel blockers | EURO-CELTIQUE S.A. (LU) | 2006-04-04 | — | — | US | claimed |
| EP-1532119-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-05-25 | — | — | EP | claimed |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | PURDUE PHARMA L.P. | 2004-07-08 | — | — | US | claimed |
| WO-2004011439-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | claimed |
| US-7022714-B2 | Aryl substituted benzimidazoles and their use as sodium channel blockers | EURO-CELTIQUE S.A. (LU) | 2006-04-04 | — | — | US | disclosed |
| EP-1532119-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-05-25 | — | — | EP | disclosed |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | PURDUE PHARMA L.P. | 2004-07-08 | — | — | US | disclosed |
| WO-2004011439-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | CACNA1S, CACNA1I, SCN1A | NPY1R 2315/4885MCHR1 3807/4885SCN9A 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.